Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01992705
Other study ID # HP-00055716
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 2014
Est. completion date September 27, 2018

Study information

Verified date August 2019
Source University of Maryland, Baltimore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objective: To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy.

Secondary Objective(s):

1. To assess the disease-free-survival, overall survival, time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT

2. To investigate the safety and tolerability of FOLFIRINOX and SBRT in patients with resectable pancreatic cancer

3. To determine the radiologic and pathological response associated with preoperative SBRT and FOLFIRINOX therapy

4. To assess quality of life through and after treatment using the FACT-Hep questionnaire


Description:

The study investigators hypothesize that neoadjuvant FOLFIRINOX can be safely and efficaciously delivered using a sequential regimen with SBRT as an alternative to standard neoadjuvant chemoradiotherapy. Standard of care neoadjuvant treatment typically requires about six weeks of treatment with sub-systemic dosing of chemotherapy. The feasibility of the sequential delivery of the FOLFIRINOX followed by SBRT will be evaluated by capturing the prevalence of grade 3 toxicity and the treatment delay rate.

In our study, SBRT is planned sequentially to follow cycle 4 of chemotherapy treatment, provided toxicity has resolved to grade 2 or less. Thus, allowing for resolution of chemotherapy toxicity prior to initiation of radiation therapy. This interval and the fact that there is no concurrent delivery of chemo-RT, based on previously discussed experiences, including approaches where SBRT safely follows other intense chemotherapy regimens (see Polistina et al and Chuong [35,36]) makes this study feasible without establishing toxicity profile.

The proposed regimen of 4 cycles of FOLFIRINOX followed by 30 Gy/5 fractions using SBRT will be safely tolerated and will improve resectability rates in borderline resectable PDAC patients. In addition, this regimen will not compromise the ability to achieve a successful Whipple resection.

This regimen will improve the local control rate and overall disease free survival in this patient population. The investigators further hypothesize that early administration of FOLFIRNOX will provide optimal systemic therapy to control clinically occult micrometastases.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date September 27, 2018
Est. primary completion date September 27, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years at diagnosis.

- Biopsy proven pancreatic adenocarcinoma.

- Borderline resectable per NCCN criteria (No distant metastases, venous involvement of the portal vein/SMV, demonstrating tumor abutment and narrowing of the lumen, encasement of the portal vein/SMV without encasement of the nearby arteries, or short-segment venous occlusion resulting from either tumor thrombus or encasement but with suitable vessel proximal or distal to this area of vessel involvement, allowing for safe resection and reconstruction; gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery, without extension to the celiac axis; tumor abutment of the SMA not to exceed 180 degrees of the circumference of the vessel wall.).

- Radiologically measurable or clinically evaluable disease.

- Pancreas protocol CT and/or MRI if required for further clarification of disease tissue planes within 4 weeks of registration.

- ECOG PS of 0-2.

- Able to get a Whipple resection per surgeon assessment performed within 4 weeks of registration.

- The following laboratory values obtained = 28 days prior to registration:

- Absolute neutrophil count (ANC) = 1,500/mm3.

- Platelet count = 100,000/mm3.

- Hemoglobin > 8.0 g/dL.

- Total bilirubin = 1.5 x upper limit of normal (ULN).

- SGOT (AST) = 2 x ULN.

- SGPT (ALT) = 2 x ULN.

- Creatinine = 1.5 x ULN.

- CA 19-9 level (to establish baseline).

- A negative pregnancy test within 7 days prior to registration for women of childbearing potential. In addition, male and female participants must commit to adequate contraception while on study.

- Able to provide written informed consent.

- Willing to return for all required study assessments.

- Neurological assessment for pre-existing peripheral neuropathy.

- Documentation of pre-existing hearing deficits.

Exclusion Criteria:

- Any pancreatic adenocarcinoma that does not meet criteria for borderline resectable disease.

- Prior history of abdominal radiation therapy.

- History of autoimmune disease such as scleroderma, lupus, and inflammatory bowel disease.

- Patients with tumor-caused symptomatic bowel obstruction.

- Chemotherapy (including hormonal therapy) within the past 5 years from date of registration.

- Other invasive malignancies within the past 5 years from date of registration.

- Pregnant or nursing women or women of childbearing age that are unwilling to employ adequate contraception.

- Other co-morbid conditions which, based on the judgment of the physicians obtaining informed consent, would make the patient inappropriate for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable
Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
Drug:
-Oxaliplatin 85 mg/m2 IV on Day 1
Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
-Irinotecan 180 mg/m2 IV on Day 1
Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.

Locations

Country Name City State
United States University of Maryland Medical Center Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of adverse events/toxicites reported during and following treatment of FOLFIRINOX and SBRT in patients with resectable pancreatic cancer Number of toxicities participants reported by participants during and following treatment with FOLFIRINOX and SBRT in patients with resectable pancreatic cancer (NIH CTCAE v.4). Participants will be followed from randomization up to 120 months or death (from any cause) whichever comes first.
Other Radiologic and pathological response associated with preoperative SBRT and FOLFIRINOX therapy To determine the radiologic and pathological response associated with preoperative SBRT and FOLFIRINOX therapy (review of radiology and pathology reports). Participants will be followed from randomization up to 120 months or death (from any cause) whichever comes first.
Other Quality of life through and after treatment To assess quality of life through and after treatment using the FACT-Hep questionnaire Participants will be followed from randomization up to 120 months or death (from any cause) whichever comes first.
Primary Rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy. To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy (AGGC 6th edition). Participants will be followed from randomization up to 120 months or death (from any cause) whichever comes first.
Secondary Survival status (disease-free-survival vs. overall survival) time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT To assess the disease-free-survival, overall survival, time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT (RECIST) Participants will be followed from randomization up to 120 months or death (from any cause) whichever comes first.
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02243007 - Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT05679050 - Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Withdrawn NCT01694589 - A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Phase 0
Active, not recruiting NCT03138720 - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Phase 2
Completed NCT01298011 - Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer Phase 2
Completed NCT06363084 - A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Recruiting NCT04810910 - Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Phase 1
Recruiting NCT05624918 - A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Phase 2
Completed NCT02047513 - Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Phase 2
Completed NCT02115022 - EUS vs. MDCT in Pancreatic Malignancy
Recruiting NCT03492671 - Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer Phase 2
Terminated NCT05546411 - A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer Phase 2
Not yet recruiting NCT06172036 - Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab Phase 2
Recruiting NCT05788744 - Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer N/A
Recruiting NCT04737551 - Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
Recruiting NCT03822936 - Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma Phase 2
Completed NCT03435536 - Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer N/A